Corporate

Overview

At Michael Best, we understand the value of long-term relationships. Clients count on our Corporate group for strategic legal counsel throughout the entire business life cycle — from organization, financing, and operation through mergers, acquisitions, divestitures, and liquidation.

Our clients span many different industries and include all sizes of public and private companies, individual and institutional investors, family and wealth preservation and transfer trusts, and other business entities. We work closely with each client to develop a deep understanding of its business, objectives, communication styles, and company culture.

Our Corporate service areas are listed below and briefly outlined on the linked pages. Because each client is unique, we employ a tailored approach to deliver the right combination of legal services and guidance at every stage of business.

Service Areas

Securities & Capital Markets

Transactions

General Corporate Counsel

Venture Capital & Private Equity

Healthcare

Environmental, Social & Governance

Debt Finance

Experience

  • Represented one of the world’s largest manufacturers of frozen foods in its acquisition of substantially all the assets of a frozen food manufacturer and distributor. We provided counsel in all aspects of M&A, including due diligence, document drafting, and structuring for tax purposes.
  • Represented a regenerative medicine company in its merger with a global specialty biopharmaceutical company, which involved cash consideration at closing and cash consideration tied to certain FDA regulatory approvals and revenue from product sales.
  • Represented a pharmaceutical company that develops novel compounds for the treatment of schizophrenia and other central nervous system disorders. Michael Best advised the company in negotiating the terms of a $26 million Series C financing and in corporate governance matters related to the financing.
  • Represented the lead investor in a Wisconsin-based developer of new technologies and production methodologies in nuclear medicine through its first three rounds of financing. The developer undertook a complex recapitalization to simplify its capital structure and position itself for new financing. We represented the lead investor in negotiating the terms of the recapitalization and a new $20 million convertible note financing. The developer is among those to create a domestic source of molybdenum-99 (Moly 99), the basis for the medical isotope technetium-99, which is used in medical scans to diagnose heart disease and cancer.

Primary Contact

Insights

Primary Contact

back to top